Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

被引：26
作者：
Baselga, Jose [1 ]
Mendelsohn, John [2 ]
机构：
[1] Hosp Gen Univ Vall DHebron, Barcelona 08035, Spain
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 1997年 / 2卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Tyrosine kinase receptors; monoclonal antibodies; breast cancer; tyrosine kinase inhibitors; epidermal growth factor receptor; HER2/neu; erbB2;
D O I：
10.1023/A:1026355831693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast carcinomas express high levels of type I tyrosine kinase receptors and their ligands. For these reason therapies directed at these receptors have the potential to be useful anti-cancer agents. A series of monoclonal antibodies (MAbs)(3) directed against the EGF receptor and the closely related erbB2/HER2/neu receptor are currently under evaluation. These MAbs have shown promising preclinical activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions. These antibodies are currently being tested in clinical trials either alone or in combination with chemotherapeutic agents. Clinical activity with anti-HER2/neu MAbs has been documented in patients with advanced breast cancer. In addition, compounds that inhibit receptor tyrosine kinases have shown significant preclinical activity and are potential candidates for clinical testing.
引用
收藏
页码：165 / 174
页数：10
相关论文
共 50 条
[41]   Exploring receptor tyrosine kinases-inhibitors in Cancer treatments [J].
D. Samuel Metibemu ;
O. Adeboye Akinloye ;
A. Jamiu Akamo ;
D. Ajiboye Ojo ;
O. Tolulope Okeowo ;
I. Olaposi Omotuyi .
Egyptian Journal of Medical Human Genetics, 20
[42]   The ErbB/HER receptor protein-tyrosine kinases and cancer [J].
Roskoski, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 319 (01) :1-11
[43]   Interplay between receptor tyrosine kinases and hypoxia signaling in cancer [J].
Glueck, Astrid A. ;
Aebersold, Daniel M. ;
Zimmer, Yitzhak ;
Medova, Michaela .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2015, 62 :101-114
[44]   Aurora kinases: novel anti-breast cancer targets [J].
Yiliyaer ;
Yusufu Maimaiti .
OncologyandTranslationalMedicine, 2019, 5 (01) :43-48
[45]   Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer [J].
Moody, Terry W. ;
Ramos-Alvarez, Irene ;
Jensen, Robert T. .
BIOLOGY-BASEL, 2023, 12 (07)
[46]   Targeting IκappaB kinases for cancer therapy [J].
Awasthee, Nikee ;
Rai, Vipin ;
Chava, Srinivas ;
Nallasamy, Palanisamy ;
Kunnumakkara, Ajaikumar B. ;
Bishayee, Anupam ;
Chauhan, Subhash C. ;
Challagundla, Kishore B. ;
Gupta, Subash C. .
SEMINARS IN CANCER BIOLOGY, 2019, 56 :12-24
[47]   Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer [J].
Xu, Yi-chao ;
Wang, Xiang ;
Chen, Yi ;
Chen, Si-meng ;
Yang, Xin-ying ;
Sun, Yi-ming ;
Geng, Mei-yu ;
Ding, Jian ;
Meng, Ling-hua .
THERANOSTICS, 2017, 7 (04) :974-986
[48]   Acquired resistance to drugs targeting receptor tyrosine kinases [J].
Rosenzweig, Steven A. .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) :1041-1048
[49]   A review on tyrosine kinase inhibitors for targeted breast cancer therapy [J].
Sankarapandian, Vidya ;
Rajendran, Ramya Lakshmi ;
Miruka, Conrad Ondieki ;
Sivamani, Poornima ;
Maran, Balu Alagar Venmathi ;
Krishnamoorthy, Rajapandiyan ;
Gangadaran, Prakash ;
Ahn, Byeong-Cheol .
PATHOLOGY RESEARCH AND PRACTICE, 2024, 263 :155607
[50]   Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy [J].
Mohanraj, Lathika ;
Oh, Youngman .
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (02) :166-177
12345